| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.25 | 3e-07 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-07 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-07 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-07 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.18 | 8e-07 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.16 | 9e-07 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.17 | 9e-07 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-06 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.29 | 1e-06 |